Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
iX Biopharma Ltd. (SG:42C)
SGX:42C
Holding SG:42C?
Track your performance easily
42C Stock Chart & Stats
Day’s RangeS$0 - S$0
52-Week RangeS$0.02 - S$0.06
Previous CloseS$0.02
Volume0.00
Average Volume (3M)226.14K
Market Cap
S$19.35M
Enterprise ValueS$17.38M
Total Cash (Recent Filing)S$6.21M
Total Debt (Recent Filing)S$4.24M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Feb 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume33,530
30 Day Avg. Volume226,136
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
iX Biopharma Ltd. News
PremiumCompany Announcements
iX Biopharma’s iXB 401: A Breakthrough in Drug Delivery
PremiumCompany Announcements
iX Biopharma Unveils Growth Plans at AGM
PremiumCompany Announcements
iX Biopharma Ltd. Holds Key Shareholder Meeting
PremiumCompany Announcements
iX Biopharma Restructures Board Committees for Efficiency
PremiumCompany Announcements
iX Biopharma Welcomes Aging Expert to Advisory BoardPremiumCompany Announcements
iX Biopharma Advances Global Licensing of Wafermine
PremiumCompany Announcements
iX Biopharma’s New Wafer Revolutionizes NAD+ SupplementationPremiumCompany Announcements
iX Biopharma’s CBD Wafer Shows Promise for Kidney Failure SymptomsOptions Prices
Currently, No data available
---
Ownership Overview
42C FAQ
What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.02 and its highest was S$0.06 in the past 12 months.
What is iX Biopharma Ltd.’s market cap?
Currently, no data Available
When is iX Biopharma Ltd.’s upcoming earnings report date?
iX Biopharma Ltd.’s upcoming earnings report date is Feb 07, 2025 which is in 48 days.
How were iX Biopharma Ltd.’s earnings last quarter?
iX Biopharma Ltd. released its earnings results on Aug 23, 2024. The company reported -S$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.004.
Is iX Biopharma Ltd. overvalued?
According to Wall Street analysts iX Biopharma Ltd.’s price is currently Overvalued.
Does iX Biopharma Ltd. pay dividends?
iX Biopharma Ltd. does not currently pay dividends.
What is iX Biopharma Ltd.’s EPS estimate?
iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iX Biopharma Ltd. have?
iX Biopharma Ltd. has 841,257,700 shares outstanding.
What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
iX Biopharma Ltd. reported an EPS of -S$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of iX Biopharma Ltd.?
Currently, no hedge funds are holding shares in SG:42C
---
iX Biopharma Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.51%
12-Months-Change
Fundamentals
Return on Equity
-106.91%
Trailing 12-Months
Asset Growth
-41.34%
Trailing 12-Months
Company Description
iX Biopharma Ltd.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in Singapore, Australia, and China, of which the majority of the revenue comes from China..
---
Technical Analysis
---